By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ariad Pharmaceuticals, Inc. 

26 Landsdowne Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-494-0400 Fax: 617-494-8144


ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit or follow ARIAD on Twitter (@ARIADPharm).

Key Statistics

Ownership: Public

Web Site: Ariad
Symbol: ARIA

Company News
Ariad (ARIA) To Webcast Conference Call On First Quarter 2015 Financial Results 4/23/2015 10:15:55 AM
Ariad (ARIA) Announces Issuance Of Key U.S. Patent On Brigatinib 4/22/2015 10:40:14 AM
Why Ariad (ARIA) Could Be Worth $3 Billion to a Big Drugmaker 4/22/2015 6:05:45 AM
Ariad (ARIA) Announces Results Of Preclinical Studies On Brigatinib At The AACR Annual Meeting 4/21/2015 11:27:41 AM
Ariad (ARIA) Presents Updated Clinical Data On Brigatinib In Patients With ALK+ Non-Small Cell Lung Cancer 4/17/2015 10:38:49 AM
As Proxy Fight Continues, Five Companies That May be Eyeing Ariad (ARIA) 4/15/2015 6:34:46 AM
Ariad (ARIA) Announces Approval Of Iclusig (As Ponatinib Hydrochloride) In Canada 4/6/2015 7:58:46 AM
Ariad (ARIA) Announces Dismissal Of Shareholder Class Action Lawsuit In Federal District Court 3/25/2015 10:04:59 AM
Ariad (ARIA) And Medison Pharma Ltd. Announce Approval Of Iclusig (Ponatinib) In Israel 3/24/2015 10:59:00 AM
Ariad (ARIA) Announces Presentations Of Preclinical Data At American Association for Cancer Research Annual Meeting 3/19/2015 10:38:41 AM